Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30353266 | 1.00 | ALDH1A1 (0.56) | ALDH1A1TDP1MAPTKDM4EVCAM1 | |
| SCHEMBL21824095 | 0.85 | ALDH1A1 (0.60) | ALDH1A1TDP1MAPTKDM4ECYP4F2 | |
| SCHEMBL325356 | 0.81 | VCAM1 (0.46) | ALDH1A1TDP1MAPTKDM4EVCAM1 | |
| SCHEMBL30995113 | 0.81 | VCAM1 (0.46) | ALDH1A1TDP1MAPTKDM4EVCAM1 | |
| SCHEMBL17922634 | 0.81 | CYP4F2 (0.46) | ALDH1A1TDP1MAPTKDM4ECYP4F2 | |
| SCHEMBL21824100 | 0.81 | ALDH1A1 (0.59) | ALDH1A1TDP1MAPTKDM4ECYP4F2 | |
| SCHEMBL30353239 | 0.81 | CYP4F2 (0.46) | ALDH1A1TDP1MAPTKDM4ECYP4F2 | |
| SCHEMBL21824145 | 0.80 | ALDH1A1 (0.58) | ALDH1A1TDP1MAPTKDM4ECYP4F2 | |
| SCHEMBL21824057 | 0.80 | ALDH1A1 (0.58) | ALDH1A1TDP1MAPTKDM4ELMNA | |
| SCHEMBL19763065 | 0.80 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPTKDM4ECYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497377-B2 | Tricyclic spiro compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-12-16 | — | — | US | disclosed |
| CN-111039916-B | Tricyclic spiro compounds | 小野药品工业株式会社 | 2023-04-28 | — | — | CN | disclosed |
| US-20220048881-A1 | TRICYCLIC SPIRO COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-17 | — | — | US | disclosed |
| US-20220048881-A1 | TRICYCLIC SPIRO COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-17 | — | — | US | disclosed |
| US-11192876-B2 | Tricyclic spiro compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-12-07 | — | — | US | disclosed |
| US-11192876-B2 | Tricyclic spiro compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-12-07 | — | — | US | disclosed |
| EP-3482760-B1 | COMBINATION COMPRISING EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | ONO PHARMACEUTICAL CO (JP) | 2021-11-10 | — | — | EP | disclosed |
| EP-3482760-B1 | COMBINATION COMPRISING EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | ONO PHARMACEUTICAL CO (JP) | 2021-11-10 | — | — | EP | disclosed |
| US-11065226-B2 | Combination comprising EP4 antagonist and immune checkpoint inhibitor | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-07-20 | — | — | US | disclosed |
| US-11065226-B2 | Combination comprising EP4 antagonist and immune checkpoint inhibitor | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-07-20 | — | — | US | disclosed |
| CN-107108480-B | Tricyclic spiro compounds | 小野药品工业株式会社 | 2020-01-17 | — | — | CN | disclosed |
| US-20190255013-A1 | COMBINATION COMPRISING EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-22 | — | — | US | disclosed |
| US-20190255013-A1 | COMBINATION COMPRISING EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-22 | — | — | US | disclosed |
| EP-3482760-A1 | COMBINATION COMPRISING EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | Ono Pharmaceutical Co., Ltd. (JP) | 2019-05-15 | — | — | EP | disclosed |
| EP-3482760-A1 | COMBINATION COMPRISING EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | Ono Pharmaceutical Co., Ltd. (JP) | 2019-05-15 | — | — | EP | disclosed |
| US-20180319764-A1 | TRICYCLIC SPIRO COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-11-08 | — | — | US | disclosed |
| US-10077247-B2 | Tricyclic spiro compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-09-18 | — | — | US | disclosed |
| US-20180002308-A1 | TRICYCLIC SPIRO COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-3243813-A1 | TRICYCLIC SPIRO COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2017-11-15 | — | — | EP | disclosed |
| WO-2016111347-A1 | TRICYCLIC SPIRO COMPOUND | 小野薬品工業株式会社 | 2016-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002308-A1 | TRICYCLIC SPIRO COMPOUND | PTGER4, PTGER1, PTGER3 | ALDH1A1 944/4885TDP1 4215/4885MAPT 4622/4885 |
| US-11192876-B2 | Tricyclic spiro compound | PTGER4, PTGER1, PTGER3 | ALDH1A1 764/4885TDP1 4297/4885MAPT 4700/4885 |
| US-10077247-B2 | Tricyclic spiro compound | PTGER4, PTGER1, PTGER3 | ALDH1A1 944/4885TDP1 4215/4885MAPT 4622/4885 |
| US-20220048881-A1 | TRICYCLIC SPIRO COMPOUND | PTGER4, PTGER1, PTGER3 | ALDH1A1 764/4885TDP1 4297/4885MAPT 4700/4885 |
| US-11065226-B2 | Combination comprising EP4 antagonist and immune checkpoint inhibitor | CD274, PTGER4, PTGER1 | ALDH1A1 281/4885TDP1 2865/4885MAPT 4312/4885 |
| US-20190255013-A1 | COMBINATION COMPRISING EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | CD274, PTGER4, PTGER1 | ALDH1A1 281/4885TDP1 2865/4885MAPT 4312/4885 |
| US-12497377-B2 | Tricyclic spiro compound | PTGER4, PTGER1, PTGER3 | ALDH1A1 764/4885TDP1 4297/4885MAPT 4700/4885 |
| US-20180319764-A1 | TRICYCLIC SPIRO COMPOUND | PTGER4, PTGER1, PTGER3 | ALDH1A1 944/4885TDP1 4215/4885MAPT 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.